Latest Urology News
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Perioperative red blood cell transfusion linked to increased adjusted odds of VTE, DVT, PE.
Over 12 weeks of treatment, the mean number of nocturia episodes decreased by 1.1 and 0.9 in men who were and were not bothered by their symptoms, a non-significant difference between groups.
Clinicians can rest easier about recommending finasteride to more men, according to experts.
Men with erectile dysfunction (ED) are almost twice as likely to experience a cardiovascular event as those without ED.
Those with worse emotional distress also report worse urinary, sexual, bowel functions.
If externally validated, bpMRI could be used to triage men for prostate biopsy.
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
98.4% of respondents report moderate, severe shortages of morphine, hydromorphone, fentanyl.
New findings from the CARMENA trial contradict previous research showing better survival from cytoreductive nephrectomy followed by targeted therapy.
Greater decrease in total UI frequency with yoga intervention versus time-and-attention control group.
May be as effective as full-dose direct oral anticoagulants for extended-duration treatment.
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
Benefit of palliative radiation for bone metastasis across age groups; older age should not preclude tx.
Findings for men with intermediate- and high-risk prostate cancer.
Lower rate of VTE recurrence, but higher clinically relevant non-major bleeding versus dalteparin.
In a meta-analysis, smokers had an 89% greater risk of dying from prostate cancer compared with nonsmokers.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)